158 related articles for article (PubMed ID: 32210157)
1. Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study.
Paleari L; Rutigliani M; Siri G; Provinciali N; Colombo N; Decensi A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210157
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
3. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R
Gynecol Oncol; 2021 Apr; 161(1):160-165. PubMed ID: 33608144
[TBL] [Abstract][Full Text] [Related]
6. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.
Tomica D; Ramić S; Danolić D; Šušnjar L; Perić-Balja M; Puljiz M
J Obstet Gynaecol; 2018 Jan; 38(1):96-102. PubMed ID: 28764605
[TBL] [Abstract][Full Text] [Related]
7. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
8. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.
Suh KJ; Kim SH; Lee KH; Kim TY; Kim YJ; Han SW; Kang E; Kim EK; Kim K; No JH; Han W; Noh DY; Lee M; Kim HS; Im SA; Kim JH
Cancer Res Treat; 2017 Oct; 49(4):1153-1163. PubMed ID: 28253566
[TBL] [Abstract][Full Text] [Related]
9. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
[TBL] [Abstract][Full Text] [Related]
10. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
12. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Serkies K; Abacjew-Chmyłko A; Wieczorek-Rutkowska M; Pęksa R
Ginekol Pol; 2018; 89(11):607-610. PubMed ID: 30508212
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
15. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
16. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
[TBL] [Abstract][Full Text] [Related]
17. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.
Yu KD; Di GH; Wu J; Lu JS; Shen KW; Liu GY; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1347-54. PubMed ID: 18488249
[TBL] [Abstract][Full Text] [Related]
19. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Anderson H; Hills M; Zabaglo L; A'hern R; Leary AF; Haynes BP; Smith IE; Dowsett M
Ann Oncol; 2011 Aug; 22(8):1770-6. PubMed ID: 21285137
[TBL] [Abstract][Full Text] [Related]
20. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]